胃癌患者血清可溶性IL-2受体、T细胞亚群及NK细胞的临床观察  

The clinical investigation of serum soluble interleukin-2 receptor,T cell subsets and natural killer cells in patients with gastric cancer

作　　者：卢雪峰[1] 赵宪邨[1] 尹秀玲[1] 潘祥林[1] 王岩 

机构地区：[1]山东医科大学附属医院内科,济南250012

出　　处：《胃肠病学和肝病学杂志》1999年第4期277-278,共2页Chinese Journal of Gastroenterology and Hepatology

摘　　要：目的　较全面地观察胃癌患者的细胞免疫功能 ,为胃癌的预测、诊断、病情估计及免疫治疗提供依据。方法　应用酶联免疫双抗夹心法 (ELISA)及碱性磷酸酶抗碱性磷酸酶 (APAAP)桥联酶标法 ,检测 3 4例胃癌患者与对照者血清可溶性白细胞介素 -2受体 (sIL -2R)、T淋巴细胞亚群及自然杀伤 (NK)细胞。结果　胃癌患者sIL-2R水平明显高于对照组 (P <0 0 1) ,Ⅲ、Ⅳ期高于Ⅰ、Ⅱ期 (P <0 0 1) ;CD4、CD8、CD4/CD8低于对照组 (P <0 .0 5 ) ,Ⅲ、Ⅳ期低于Ⅰ、Ⅱ期 (P<0 0 5 ) ;NK细胞百分比显著低于对照组 (P <0 0 1) ,Ⅲ、Ⅳ期明显低于Ⅰ、Ⅱ期 (P <0 0 1)。结论　多指标检测表明胃癌病人细胞免疫功能明显下降。推测细胞免疫功能下降、免疫监视功能低下可能是患胃癌的重要原因 ;检测细胞免疫功能对胃癌的预测、诊断、病情估计及免疫治疗的选择均有重要价值。Aim Completely investigating the cellular immunological function in order to provide the proof about the prediction,diagnosis,evaluation and immunotherapy of gastric cancer(GC). Methods Sandwiched enzymelinked immunosorbent assay (ELISA) and alkaline phosphatase antialkaline phosphatase (APAAP) were used to detect the serum sIL-2R,T-lymphocyte subsets and natural killer (NK)cells in 34 GC cases and in the control group. Restults The serum sIL-2R level in GC was obviously higher than that in the control group (p<0.01),that in Stage Ⅲ and Ⅳ was higher than that in Stage Ⅰ and Ⅱ (P<0.01);CD + 4,CD + 8, and CD +/CD + 8 were lower than those in the control group (P<0.01),those in stage Ⅲ and Ⅳ were lower than those in Stage Ⅰand Ⅱ (P<0.05);the percentage of NK cells was significantly lower than that in the control group (P<0.01),that in Stage Ⅲ and Ⅳ was lower than that in Stage Ⅰ and Ⅱ(P<0.01).Conclusions The results of this study suggested that the cellular immunological function in patients with GC obviously decreased.The decrease of cellular immunity and immunosurveillance might be the important cause of GC;It is of great value for the prediction,diagnosis,evaluation and immunotherapy selection to detect the celluar immunological function.

关 键 词：胃癌 细胞免疫 SIL-2R T细胞亚群 NK细胞 

分 类 号：R735.203[医药卫生—肿瘤]